Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--According to a comprehensive market report authored by DeciBio Consulting LLC, “Oncology Liquid Biopsy (LBx) Market Report 2024 – 2029,” the global oncology liquid biopsy market is predicted to reach $10.1B by 2029, driven by a broad push for increased biomarker testing globally, updated testing guidelines, and expansion in coverage for testing.

This third-edition of DeciBio’s liquid biopsy report takes an updated and comprehensive look at the LBx landscape. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key LBx market segments.

Advancements in sensitivity and analytical capabilities are expanding the use-cases for liquid biopsy beyond genomic profiling to include minimal / molecular residual (MRD) testing, recurrence monitoring (surveillance), treatment response monitoring, and early cancer detection. While nascent today, these new applications represent significant global market expansion opportunities.

Report Methodology / Scope:

Report Details
Research Methods	Secondary research: publication analysis of LBx-related congress abstracts published from 2023-1H 2024, review of company websites and publications, identification and characterization of LBx clinical trials Primary research: interviews with 38 oncology stakeholders across the U.S., EU, APAC, and ROW, including oncologists, pathologists and pharma; survey of 207 primary care physicians and specialists to assess current and expected future utilization and perspectives on blood-based early cancer detection testing Proprietary databases / analysis: use of internal databases and tools (e.g., BioTrack, Dexter expert network), including DeciBio’s Discovery Portal and DeciBio DxBooks Market analysis: 4 independent market models, including a mix of top-down and bottom-up approaches
2029 Market Size	$10.1 billion
CAGR (2024-2029)	29%
Base Year	2024 (current)
Forecast Period	2024-2029
Market / Forecast Currency	USD
Report Coverage	Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis
Segments Covered	Customer (clinical, biopharma) Tumor type (lung cancer, breast cancer, colorectal cancer, other) Application (early cancer detection, therapy selection, minimal residual disease, monitoring / surveillance, biopharma translational research) Business model (in-house (kits), send-out (services)) Competitor, grouped into tiers (Foundation Medicine, Guardant, Caris, Tempus, NeoGenomics, LabCorp, QuestDx, Burning Rock, Natera, Exact Sciences, Personalis, Illumina, Thermo Fisher, Freenome, Academic Medical Centers (with a proprietary LBx offering offered externally), other) Geography (U.S., Europe, APAC, rest of the world)

Learn more about DeciBio’s Oncology Liquid Biopsy (LBx) Market Report 2024 – 2029, here: https://www.decibio.com/product/global-oncology-liquid-biopsy-manufacturing-market-report

Selection of Liquid Biopsy Companies Mentioned:

• Adela
• AmoyDx
• Berry Oncology
• Biological Dynamics
• Burning Rock Biotech
• Caris Life Sciences
• DELFI Diagnostics
• Exact Sciences
• Foresight Diagnostics
• Foundation Medicine
• Freenome
• Geneseeq Technology Inc.
• Genetron Holdings
• GRAIL
• Guardant Health
• Illumina
• LabCorp / PGDx
• Tempus
• Thermo Fisher Scientific
• Natera
• NeoGenomics (Inivata)
• Personalis
• Predicine
• Roche
• SeekIn
• Singlera Genomics
• Strata Oncology
  
  

Liquid Biopsy Market Analysis:

Market Drivers

The liquid biopsy market is poised for growth, driven by new evidence, updated guidelines, and expanded coverage that support broader application beyond primary use cases, such as therapy selection in lung cancer and MRD / monitoring in colorectal cancer. As new biomarkers emerge and companion diagnostics are approved, the demand for biomarker testing is on the rise. This increasing demand puts pressure on limited tissue samples and accelerates the adoption of LBx testing, particularly as patients become eligible for multiple LBx tests throughout their treatment journey. The availability of next-generation LBx assays, featuring improved performance and the ability to detect emerging biomarkers, expands the use cases for LBx testing and advances translational research in pharma. While the U.S. leads in the clinical use of LBx testing, new partnerships aimed at increasing global access to LBx testing will support further market growth globally.

Market Moderators

Test cost and the pace and level of payor coverage remains a challenge for liquid biopsy testing, especially outside of lung cancer and in ex-U.S. markets. Novel modalities, such as multiomics-based LBx tests and MRD / surveillance testing, can be prohibitively expensive to implement at scale in large trials and similarly, when considering adoption in routine clinical testing. Early cancer detection, though an application of LBx testing with high-growth potential, has recently faced headwinds with lower-than-expected performance in pivotal studies. Additionally, the broader macroeconomic environment has forced companies to focus on near-term profitability and to reduce or delay investment and R&D for emerging applications and use cases.

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.